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Abstract
Introduction: Lifetime number of years of menstruation (LNYM) reflects a woman’s 
cumulative exposure to endogenous estrogen and can be used as a measure of the 
combined effect of reproductive factors related to endometrial cancer (EC) risk.
Material and methods: We aimed to study the association between LNYM and EC 
risk among postmenopausal women and calculate the population attributable frac-
tion of EC for different LNYM categories. Our study sample consisted of 117 589 
women from the Norwegian Women and Cancer (NOWAC) Study. All women were 
aged 30- 70 years at enrollment and completed a baseline questionnaire between 
1991 and 2006. Women were followed up for EC to December 2014 through linkages 
to national registries. We used Cox proportional hazards models to estimate hazard 
ratios with 95% confidence intervals (95% CIs), adjusted for potential confounders.
Results: In all, 720 women developed EC. We found a statistically significant, positive 
dose- response relation between LNYM and EC, with a 9.1% higher risk for each ad-
ditional year of LNYM (P for trend < .001). Using the LNYM category ≥40 as a refer-
ence, the hazard ratios for LNYM <25, 25- 29, 30- 34, 35- 39 were 0.17 (95% CI 
0.22- 0.27), 0.25 (95% CI 0.17- 0.36), 0.43 (95% CI 0.32- 0.58), and 0.68 (95% CI 0.51- 
0.92), respectively. The association between LNYM and EC was independent of in-
complete pregnancies, menopausal hormone therapy, diabetes, and body mass index. 
When considering the population attributable fraction, 67% of EC was estimated to 
be attributable to LNYM ≥25 years.
Conclusions: Our study supports that increasing LNYM is an important and inde-
pendent predictor of EC risk.
K E Y W O R D S
endometrial cancer, menopause, number of menstruations, prospective study, reproductive 
factors
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1  | INTRODUC TION
Endometrial cancer (EC) is the sixth most common cancer among 
women worldwide and the most common gynecological cancer in the 
western world.1 In Norway, EC incidence rates have increased mark-
edly in the last decades,2 with age- standardized rates of 19.7 per 
100 000 person- years reported in the period 1982- 1986 and 27.6 
per 100 000 person- years in the period 2012- 2016.3 Furthermore, EC 
incidence rates in Norway are predicted to increase by 57% in 2025, 
compared with the rates observed in 2005.4
Among women, menstrual and reproductive factors, such as 
earlier age at menarche,5-9 later age at menopause,5-8,10,11 nullipar-
ity, and/or nulligravidity,5-9,12-17 contribute to hormonal changes, 
the effects of which play an important role in the development of 
hormone- related cancers. Indeed, these factors might be linked 
to prolonged, excessive exposure of endometrial cells to estro-
gen, leading to an increased EC risk. Conversely, full- term preg-
nancies,9,14 later age at last birth,5,16,17 and breastfeeding5,9,12,13 
play a protective role in EC risk due to prolonged exposure to 
progesterone. Studies that investigated the relation between in-
complete pregnancies and EC risk provided controversial results, 
showing no association,5,12,18-21 inverse association9,16,22 or even 
increased risk.8 Lifetime number of years of menstruation (LNYM) 
can be used as a composite variable to summarize the effect of 
the above- mentioned factors and indirectly measure cumulative 
exposure to endogenous hormones during a woman’s reproduc-
tive years.
Several epidemiological studies have prospectively investigated 
the combined impact of menstrual and reproductive factors on EC 
risk. The most cited reports investigated the effect of number of 
years of ovulation or total menstrual lifespan.5,8,9 However, studies 
based on postmenopausal populations from the USA (IOWA popu-
lation)8 and China9 were limited by a small number of cancer cases, 
and they presented age- adjusted analyses only, failing to control for 
potential risk factors. The study by Dossus et al.5 included both pre-
menopausal and postmenopausal women with heterogeneous infor-
mation on breastfeeding and number of full- term pregnancies from 
different European countries. That study presented risk estimates 
per year of menstruation, but did not show any association between 
increasing LNYM and EC.
When strong associations are observed between an outcome 
and a risk factor, population attributable fraction (PAF) is often 
used to measure the impact of that risk factor on a population 
level.23 Although recent studies have investigated the PAF of EC 
in relation to physical activity (PA), obesity, menopausal hormone 
therapy (MHT) use, parity, and breastfeeding,14,24,25 to the best of 
our knowledge, there are no published cohort studies that have 
calculated PAF with regard to a composite variable like LNYM, 
which covers cumulative menstrual and reproductive risk fac-
tors. Using a population- based cohort of Norwegian women, we 
aimed to study the association between LNYM and EC risk among 
postmenopausal women and calculate the PAF of EC for different 
LNYM categories.
2  | MATERIAL AND METHODS
2.1 | The Norwegian Women and Cancer Study
The Norwegian Women and Cancer (NOWAC) Study is an ongoing, 
nationally representative, prospective cohort study that includes 
Norwegian women aged 30- 70 years who were randomly se-
lected from the Central Population Register of Norway.26 Selected 
women received a comprehensive, eight- page, self- administered 
questionnaire, which included questions on diet, medical his-
tory, and lifestyle; and an informed consent form. Women were 
recruited during two waves of data collection (1991/97 and 
2003/06), with an overall response rate of 57% and 48.4%, re-
spectively. In total, > 172 478 women completed the enrollment 
questionnaire. Follow- up questionnaires were sent at intervals of 
6- 8 years. The external validity of the NOWAC Study is reported 
to be acceptable.27 Further details on the NOWAC Study and its 
design have been described in detail elsewhere.28
2.2 | Study sample
Women who reported that their periods stopped spontaneously 
(Do you still have regular/irregular menstruation? Did menstrua-
tion stop? yes/no) in either their baseline or follow- up question-
naire were categorized as postmenopausal and were eligible 
for inclusion (n = 159 246). We then excluded participants with 
prevalent cancer (n = 7246), those who reported hysterectomy 
or oophorectomy at baseline or follow up (n = 12 221), and those 
who emigrated or died before the start of follow up (n = 7). We 
further excluded women with missing information on years of 
menstruation (n = 11 113), which included missing information 
on age at menarche (n = 2274) and ever- use of oral contracep-
tive and duration (n = 8839). Women with missing information on 
the selected confounders: height or weight (n = 2666),24 smok-
ing status (n = 557), and PA (n = 7847) were also excluded. 
Hence, the final study cohort included 117 589 postmenopausal 
women.
2.3 | Assessment of covariates and calculation of 
lifetime number of years of menstruation
Information on the covariates age at menarche, age at menopause, 
number of full- term pregnancies, duration of breastfeeding, preg-
nancies shorter than 6 months duration, height, weight, oral con-
traceptive use, smoking status, MHT use, diabetes, and smoking 
Key Message
Higher number of years of menstruation is significantly as-
sociated with increased risk of endometrial cancer in 
Norwegian women.
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status was taken from NOWAC questionnaires. Self- reported 
height and weight29 were used to calculate body mass index 
(BMI) in kg/m2. Parity and breastfeeding variables are generally 
reported to have good validity in the NOWAC Study.27 Missing 
information on age at menopause was treated according to smok-
ing status, as women who smoke have been shown to have ear-
lier menopause.30 Mean age at menopause for current and former 
smokers in our study (49 and 50 years, respectively) was used to 
complete missing data for participants who were current or former 
smokers. For nonsmokers, missing data on age at menopause was 
set at 53 years, which has been used in the NOWAC Study be-
fore31 and represents approximately 80% of women in our study 
population. Assessment of PA level was performed as in previous 
NOWAC reports.32,33
The LNYM represented the cumulative duration of menstrual 
cycles in a woman’s lifetime. However, we used a definition that 
was slightly different from that used in the European Prospective 
Investigation into Cancer and Nutrition (EPIC) Study.34 Instead, we 
defined LNYM as the number of years between age at menarche and 
age at menopause, minus the cumulative duration of full- term preg-
nancies (calculated as the number of full- term pregnancies, including 
live and stillbirths, multiplied by 0.75 years), duration of breastfeed-
ing (calculated as the cumulative number of months of breastfeeding 
in all pregnancies), and duration of oral contraceptive use. LNYM was 
then divided into five categories: <25, 25- 29, 30- 34, 35- 39, ≥40. All 
the aforementioned variables were added on a continuous scale in 
years.
Menopausal hormone therapy is an established risk factor 
for EC35 and is also associated with menstrual characteristics.36 
However, we decided not to include MHT in the multivariable mod-
els, as this variable is included in the calculation of LNYM through 
age at menopause.
2.4 | Identification of endometrial cancer
Women with EC were identified through linkage to the Cancer 
Registry of Norway via the unique identification number assigned 
to each resident of Norway. The registry provides detailed informa-
tion on all cancer sites and histology, and covers the whole popula-
tion of Norway.3 To identify topography, we used the International 
Classification of Diseases (ICD), Revisions 7 and 10 (code 172 for 
corpus uteri cancer in ICD- 7 or corresponding code C54 in ICD- 10 
version). Morphological codes were further classified according to 
the International Classification of Diseases for Oncology, Revisions 
2 and 3. Ninety- nine percent of identified EC cases were type 1 and 
0.4% were type 2,37,38 with the following distribution of histologi-
cal subtypes: 670 (93%) endometrioid adenocarcinoma, 38 (5.3%) 
adenocarcinoma with squamous metaplasia, and <1% other types, 
including 5 (0.7%) irregular plate epithelium, 2 (0.28%) adenocarci-
noma unspecified, 1 (0.14%) undifferentiated carcinoma, 1 (0.14%) 
combined small cell carcinoma, 1 (0.14%) papillary adenocarcinoma, 
1 (0.14%) serous papillary adenocarcinoma, and 1 (0.14%) stromal 
sarcoma, respectively.
2.5 | Statistical analyses
As we studied postmenopausal women, age at inclusion into the pre-
sent study was set as the age at menopause. Therefore, we calculated 
person- years from age at menopause to the date of any incident can-
cer diagnosis (except basal cell carcinoma), emigration, death, or the 
end of the study (31 December 2014), whichever came first.
We used Cox proportional hazards regression,39 with age as the 
underlying time scale, to estimate age- adjusted and multivariable- 
adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) 
for the associations between EC and LNYM. Multivariable- adjusted 
models included BMI (normal weight: <25, overweight: 25- 29.9, 
obese: ≥30 kg/m2), smoking status (never, former, current), and 
PA level (PA <5, PA ≥5). The proportional hazards assumption was 
checked by Schoenfeld residuals, and there was no evidence of devi-
ation from proportionality. We further used Royston- Parmar flexible 
parametric proportional hazard models40 to estimate the baseline 
HRs according to different LNYM categories (Figure 1). Cubic splines 
were used to show the dose- response associations between LNYM 
and EC risk. Adjusted HRs and 95% CIs (dashed lines) were con-
structed with 4 knots based on Harrell’s default percentiles41 (see 
Supplementary material, Figure S1). We then used a Wald- type test 
to check for any nonlinear relation between LNYM and EC risk.
We performed sensitivity analyses estimating the association 
between LNYM and EC risk in each BMI category (<25, 25- 29.9, 
≥30 kg/m2) and in each PA category (PA <5, PA ≥5). We also esti-
mated Cox regression with additional adjustment for diabetes and 
MHT separately and combined. Other sensitivity analyses were 
undertaken, which included information on incomplete pregnan-
cies (abortion, yes/no; extrauterine pregnancy, yes/no). There were 
52 796 (48%) women with information on abortions (without sepa-
rating into induced or spontaneous, defined as “abortion variable” 
in our analysis), 29 250 (27%) with information available on extra-
uterine pregnancies (defined as “exu- variable” in our analysis), and 
F IGURE  1 Smoothed baseline hazard rate of endometrial 
cancer by lifetime number of years of menstruation category 
estimated with stpm2 models [Color figure can be viewed at 
wileyonlinelibrary.com].
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33 450 with information on both these variables. Therefore, we con-
structed models with 2 new LNYM values, which were calculated in 
the same manner as LNYM above, but also subtracted 12 weeks for 
each incomplete pregnancy. The value LNYM_1 included both the 
abortion and exu- variables (n = 33 450), and LNYM_2 included just 
the abortion variable (n = 65 548). Using Cox regression, we then es-
timated the association between LNYM_1 and EC risk, and between 
LNYM_2 and EC risk (data not shown). A final sensitivity analysis was 
restricted to women who had never used oral contraceptives.
We calculated the PAF to estimate the proportion of EC that could 
have been prevented in the population if women had a lower LNYM, 
using the formula: PAF = Pe*(RRe–1)/[Pe*RR + (1–Pe)], where Pe is the 
proportion of LNYM in the study population, and RRe is the relative risk 
(RR) in the final baseline multivariable proportional hazards regression 
model, including all aforementioned confounders and BMI. We calcu-
lated two- sided 95% CIs for the PAFs using the PUNAF Stata module.42
We constructed cumulative incidence rate plots for EC in the 
NOWAC Study and compared them with those of the cumulative 
incidence rate in the general Norwegian female population (see 
Supplementary material, Figure S2).
All the analyses were performed in 214 STATA version 14.0 
(Stata Corp., College Station, TX, USA).
2.6 | Ethical Approval
All procedures performed in studies involving human participants 
were in accordance with the ethical standards of the institutional 
and/or national research committee and with the 1964 Helsinki dec-
laration and its later amendments or comparable ethical standards. 
The study was approved by the Regional Committee for Medical 
Research Ethics and the Norwegian Data Inspectorate. All the par-
ticipants were informed about the study objectives and provided 
informed consent.
3  | RESULTS
Of the 117 589 included postmenopausal women, 720 devel-
oped EC during the study period. Age at EC diagnosis among our 
NOWAC participants ranged between 31 and 70 years, with a 
mean age of 62 (standard deviation [SD] 6.5) years. On average, 
participants reported age at menarche of 13 (SD 1.4) years and 
age at menopause of around 50 (SD 3.6) years (Table 1). With in-
creasing LNYM, we observed the following linear change in base-
line characteristics: decrease in age at menarche, increase in age at 
menopause, increase in nulliparity, decrease in duration of breast-
feeding, younger age at last birth, increased number of incomplete 
pregnancies, increase in mean BMI and obesity (BMI ≥30 kg/m2), 
decrease in smoking, decrease in MHT and oral contraceptive use 
among ever users, and an increase in the number of women with 
diabetes (Table 1).
Our participants breastfed for on average around 7 months 
(SD 1.0), had a mean BMI of 24.3 (SD 3.9) kg/m2, and almost half 
had at least two children and were ever users of oral contracep-
tives (n = 47 287) (Table 1). Interestingly, women who developed 
EC had a mean BMI of 26.5 (SD 5.2) kg/m2, 306 women (42.5%) 
had 2 children, only 31 (4.3%) had diabetes, 197 (27.4%) had ever 
used oral contraceptives, and 159 (22.1%) were ever MHT users 
(data not shown).
We observed a significant dose- response association between 
LNYM and EC risk (P trend <.0001). Compared with women with an 
LNYM >40 (reference group), the multivariable HR for those with 
LNYM <24, 25- 29, 30- 34, and 35- 39 were 0.17 (95% CI 0.22- 0.27), 
0.25 (95% CI 0.17- 0.36), 0.43 (95% CI 0.32- 0.58), and 0.68 (95% CI 
0.51- 0.92), respectively. For every additional LNYM, women ex-
perienced a 9.1% higher EC risk. Using the lowest LNYM category 
(LNYM <25) as a reference, as was done in previous analogue re-
ports, rendered an HR of 5.0 (95% CI 3.10- 8.03) (Table 2).
Although the test for interaction between BMI and LNYM was 
not statistically significant (P = .78), we decided to look at the asso-
ciation between EC risk and BMI in two categories, ≤24.9 and ≥25 
(Table 3). When we did this, both age- adjusted and multivariable 
analysis showed a significant (P = .0001) increased EC risk with in-
creasing LNYM.
Figure 1 illustrates age- specific HRs for EC by LNYM. All lines 
showed a sharp increase in hazards in the perimenopausal period 
and a peak in postmenopause (60- 65 years), before leveling off 
after age 70. Cubic splines illustrating dose- response associations 
between LNYM and EC risk showed nonlinearity tests of P = .001, 
and the restricted cubic splines model showed a consistent increase 
in EC risk for each additional LNYM (see Supplementary material, 
Figure S1).
Sensitivity analyses restricted to never users of oral contracep-
tion, as well as models using the values LNYM_1 (which included 
both the abortion and exu- variables) and LNYM_2 (which included 
just the abortion variable), were of similar magnitude and in line with 
the main dose- response trend. Additional stratification for PA, MHT, 
and diabetes did not attenuate these results. Tests for interaction 
between PA (PA <5, PA ≥5) and BMI (BMI ≤24.9 and BMI ≥25) were 
not significant (Table 3).
Calculations of PAF showed that if women with LNYM ≥35 could 
decrease their LNYM <35 years, 48% of EC could be avoided. The 
proportion of avoided cases increased to 64% and 67%, if LNYM 
was decreased to 20 and 25 years, respectively (see Supplementary 
material, Table S1).
4  | DISCUSSION
To the best of our knowledge, this is the first large, nationally repre-
sentative cohort study that estimated the fraction of EC in postmen-
opausal women attributable to LNYM. We observed a significant 
increase in EC risk with each additional LNYM. EC risk was more 
pronounced in women aged 50- 65 years, but this was no longer sig-
nificant after approximately 70 years of age, confirming the limited 
effect of reproductive factors in EC risk. Stratification for BMI, MHT 
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use, and diabetes did not attenuate the association between LNYM 
and EC risk.
The PAF was interpreted as the proportion of overall ECs that 
would not occur in the average population if women with an LNYM 
≥35 had an LNYM <35 (see Supplementary material, Table S1), 
assuming that the distribution of the adjustment variables remained 
unchanged. Our PAF estimates are consistent with other studies,14 
showing that reproductive factors explain almost half of EC incidence.
Several studies have investigated the association between cumu-
lative lifetime hormonal exposure and EC risk by merging the effects 
TABLE  1 Selected baseline characteristics of participants in the Norwegian Women and Cancer Study by LNYM (n = 117 589)
Characteristics
LNYM
<25 25- 29 30- 34 35- 39 ≥40
Person- years at riska 21 779 288 258 684 430 452 787 41 874
No. of endometrial cancer cases 27 60 270 314 49
Age at menarche (mean, ±SD) 13.6 (1.4) 13.6 (1.5) 13.5 (1.3) 12.8 (1.2) 12.0 (1.2)
Age at menopause (mean, ±SD)b 46.9 (5.5) 48.3 (3.5) 49.9 (2.2) 52.1 (2.5) 54.4 (2.1)
Age at first birth (mean, ± SD) 24.3 (4.9) 24.2 (4.5) 23.9 (4.3) 24.5 (4.6) 25.4 (5.1)
Age at last birth (mean, ±SD) 30.1 (5.6) 30.7 (5.2) 29.9 (5.1) 29.2 (5.1) 28.8 (5.2)
Number of full- term pregnancies (among parous women) (%)
0 8.3 5.8 4.8 13.6 43.9
1 11.8 9.2 9.0 15.7 20.3
2 42.5 37.9 42.4 45.5 25.8
3 25.8 30.9 31.4 18.9 7.1
≥4 11.6 16.2 12.5 6.2 2.9
Cumulative duration of breastfeeding (%)
0 50.3 43.9 48.9 66.9 89.8
≤1 29.4 30.7 31.9 25.3 9.0
1- 3 years 16.4 20.4 17.5 7.7 1.2
>3 years 3.9 4.9 1.7 0.2 0.0
Cumulative duration of breastfeed-
ing (years) (mean, ±SD)
0.96 (1.39) 1.08 (1.29) 0.82 (0.98) 0.49 (0.71) 0.21 
(0.47)
Number of ectopic pregnancies (%)c
Ever 1.2 1.3 1.3 1.2 0.8
Never 98.8 98.7 98.7 98.8 99.2
Number of abortions (%)d
0 71.5 69.3 65.9 68.8 75.2
1 18.7 20.4 22.7 21.2 16.0
≥2 9.7 10.3 11.4 10.0 8.8
BMI (%)
<20 kg/m2 6.9 6.2 5.6 4.9 4.3
20- 24.9 kg/m2 54.8 53.7 53.6 50.2 41.6
25- 29.9 kg/m2 29.9 31.2 31.9 33.6 36.2
≥30 kg/m2 8.4 8.9 8.9 11.4 17.9
BMI (mean, ±SD) 24.2 (3.8) 24.3 (3.8) 24.1 (3.8) 24.4 (4.1) 25.5 (4.7)
Oral contraceptive use (%)
Never 13.2 31.8 64.9 82.3 89.9
Ever 86.9 68.2 35.1 17.7 10.2
Smoking status (%)
Never 25.1 27.2 25.9 52.9 73.0
Former 38.9 39.5 38.7 28.9 18.6
Current 36.1 33.4 35.3 18.5 8.4
(Continues)
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of several hormone- related factors.43-49 In 1986, Pettersson et al. 
were the first to present a clear, dose- response association and a 4- 
fold increased EC risk with a longer menstruation span.50 Thereafter, 
other studies looked at this association using a prospective de-
sign.5,8,9 All analogue cohort and case- control studies have substan-
tial methodological heterogeneity in their construction of LNYM and 
in the number of potential confounders available for adjustment.46 In 
addition, and in contrast to other studies, we used the highest LNYM 
category (LNYM ≥40 years) as the reference category, because there 
were fewer EC in the lowest category of LNYM, and our intention 
was to show the distribution of risk estimates in 5- year intervals. 
When we ran analyses using our lowest LNYM category (LNYM <25) 
as a reference, women with >40 LNYM showed a 5- fold increased 
EC risk (HR = 5.0, 95% CI 3.10- 8.03). Nevertheless, this methodolog-
ical difference did not alter the significant dose- response association 
found in our study, which is in line with other earlier reports.
Despite the limited number of reports that directly investigated 
the association between EC risk and LNYM, there are numerous 
studies that indirectly confirmed this association by showing the ef-
fect of each individual component of LNYM. A woman’s natural men-
strual lifespan starts at menarche, is interrupted by pregnancies and 
breastfeeding periods, and ends with menopause.50 All of these fac-
tors contribute to changes in lifetime exposure to natural estrogen 
and progesterone and may, therefore, contribute to endometrial car-
cinogenesis. However, the possible long- term consequences of each 
reproductive factor differ substantially and vary across individuals.51
To minimize the possible influence of lifestyle risk factors on 
the association between LNYM and EC risk, we took into account 
the effect of BMI, MHT use, and diabetes. Obesity and overweight 
are reported to contribute to about 40% of EC cases, and accord-
ing to several reports, they confer a 4- to 6- fold increase in risk.52 
However, when we adjusted for or stratified by BMI, the results and 
dose- response trend were lightly attenuated but remained signifi-
cant, suggesting that LNYM and BMI have an independent effect on 
EC risk. These findings are in line with another recently published 
study, showing that, in comparison to genetic determinants, repro-
ductive factors are less dependent on obesity and overweight with 
regard to EC risk.45 We did not observe any changes in the main 
association when we stratified by diabetes and MHT. The possible 
effect of MHT use in our study was also ruled out by including this 
variable in multivariable- adjustment analysis and in the calculation 
of LNYM.
LNYM No. of cases




0- 24 27 0.17 (0.22- 0.27) 0.20 (0.12- 0.32)
25- 29 60 0.25 (0.17- 0.36) 0.29 (0.19- 0.42)
30- 34 270 0.43 (0.32- 0.58) 0.49 (0.36- 0.68)
35- 39 314 0.68 (0.51- 0.92) 0.75 (0.55- 1.01)
≥40 49 1.00 1.00
P for trend 0.00 0.00
Risk per year of 
menstruation
1.09 (1.08- 1.11) 1.09 (1.07- 1.11)
aMultivariable model adjusted for smoking, body mass index, and physical activity.
TABLE  2 Hazard ratios (HRs) and 95% 
confidence intervals (CI) for endometrial 
cancer by lifetime number of years of 
menstruation (LNYM) in the Norwegian 
Women and Cancer Study (n = 117 589)
Characteristics
LNYM
<25 25- 29 30- 34 35- 39 ≥40
Menopausal hormone therapy use (%)e
Never 53.9 56.3 62.3 66.1 71.5
Former 17.8 17.3 14.6 13.3 10.2
Current 18.9 17.8 17.1 16.2 14.4
Diabetes (%)f
Yes 1.6 1.7 1.7 2.1 3.4
BMI, body mass index; SD, standard deviation. Measured at baseline.
aTotal person- years = 1 685 143; average follow- up time 14.3 years (SD 7.1).
bAge at menopause is the start- age of follow up in the present study.
cInformation available in limited number of questionnaires (n = 35,540).
dWithout separating into spontaneous or induced. Information available in limited number of questionnaires (n = 65 548).
eNumber of total missing 22 147(19%).
fNumber of total missing 7336 (6.2%).
TABLE  1  (Continued)
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The relation between LNYM and EC risk is clearly biologically plau-
sible. In terms of EC development, there are 2 possible key mecha-
nisms. The first one relates to the widely proposed “estrogen window 
hypothesis,” which is based on incessant ovulation causing prolonged 
exposure to unopposed estrogen.53 The second mechanism supports 
the theory that the increased number of periods and, therefore, cy-
cles, creates incessant repeated disruption of the uterine lining and 
increases the probability of genetic alterations.8 Previous studies re-
ported a low incidence of breast and other estrogen- dependent ma-
lignancies among indigenous women. It has been shown that these 
women historically had fewer periods and ovulatory cycles during their 
life, due to multiple pregnancies and long periods of breastfeeding.54
The main strength of our study is the population- based prospec-
tive design, as the NOWAC Study is representative of Norwegian 
middle- aged women. A good illustration of this is the cumulative in-
cidence rate plots for EC constructed for both NORDCAN (Norway)2 
and NOWAC, which are matched by age group (see Supplementary 
material, Figure S2). Another important strength of our study is the 
large sample size, which gave sufficient statistical power to investi-
gate the association between LNYM and EC risk, as well as the effect 
of important confounding factors. Being population- based, our study 
is of particular interest in showing the independent association be-
tween reproductive factors and EC risk, which can likely be extrapo-
lated to similar populations. We observed normal or slightly increased 
BMI and few cases of diabetes among our participants, allowing us to 
propose that other factors might also contribute to the continuous in-
crease in EC in Norway. Along with other Scandinavian countries, and 
in contrast to several other countries in Europe, Norwegian women 
had earlier access to oral contraceptives, which were widely used in 
this study population.55 This allowed us to perform additional analy-
ses among ever users and never users of oral contraceptives and con-
clude that the dose- response relation we observed between LNYM 
and EC risk is independent of oral contraceptive use. Moreover, 99% 
of the EC cases in our study were type 1, which is believed to be 
more strongly associated with reproductive factors,38 so strengthen-
ing the plausibility of our findings. The results of sensitivity analyses 
also confirmed the validity of our LNYM variable, showing unchanged 
HRs regardless of which risk factors were included.
Our study also had several methodological limitations. First, we 
used information about past events in women’s lives, hence misclas-
sification of exposures may have occurred. However, given the pro-
spective nature of our design, if recall errors exist, we would expect 
them to be nondifferential. Second, although we were able to include 
information on incomplete pregnancies for some women, a sub-
stantial proportion of women had missing data on these variables. 
However, several studies with higher statistical power showed no 
biological evidence that incomplete pregnancies produce the equiva-
lent long- term decrease in estrogen levels that full- term pregnancies 
do with regard to hormone- dependent cancers.56 Third, due to lack 
of information on menstrual regularity, bleeding volume, anovula-
tion, and cycle length, we cannot rule out the possibility of residual 
confounding.57 Moreover, ovulatory cycles and LNYM might be inde-
pendent risk factors,58 and we could not address the potential effect 
of other bleeding problems, like secondary amenorrhea, that some 
women might experience during their reproductive life. Finally, due 
to a limited number of premenopausal EC in NOWAC, our analysis 
was restricted to postmenopausal women, which, on the other hand, 
allowed us to look at the effect of the entire menstrual span.
5  | CONCLUSION
The results indicate that a higher LNYM increases EC risk among 
postmenopausal women. Our results support the hypothesis that 
LNYM is an important tool that represents the cumulative effect of 
several risk factors and can be used to predict EC risk at a population 
level, which is, in our opinion, a better indicator of risk than each 
individual component.
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